key: cord-0884166-9zu608f7
authors: Sanna, Vanna; Satta, Sandro; Hsiai, Tzung; Sechi, Mario
title: Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition
date: 2022-01-13
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2022.114121
sha: b8c970eb4bc4ddb6bcc23d209ad859a3c4122279
doc_id: 884166
cord_uid: 9zu608f7

Recently, a novel coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised global concerns, being the etiological agent of the current pandemic infectious coronavirus disease 2019 (COVID-19). Specific prophylactic treatments like vaccines, have been authorized for use by regulatory bodies in multiple countries, however there is an urgent need to identify new, safe, and targeted therapeutics as post-exposure therapy for COVID-19. Among a plethora of potential pharmacological targets, the angiotensin-converting enzyme 2 (ACE2) membrane receptor, which plays a crucial role in viral entry, is representing an attractive intervention opportunity for SARS-CoV-2 antiviral discovery process. In this scenario, we envisioned that binding to ACE2 by multivalent attachment of ligands to nanocarriers incorporating antiviral therapeutics, it would increase receptor avidity and impart specificity to these nanovectors for host cells, particularly in the pulmonary tract, which is the primary entry route for SARS-CoV-2. Herein, we report the design and development of novel polymeric nanoparticles (NP), densely grafted with various ligands to selectively bind to ACE2, as innovative nanovectors for targeted drug delivery. We first evaluated the impact of these biocompatible targeted NP (TNP) on ligand binding toward ACE2 and measured their competition ability vs a model of spike protein (Lipo-S1). Next, we tested the effectiveness of the most performing nanoprotopype, TNP-1, loaded with a model anti-SARS-CoV-2 drug such as remdesivir (RDV), on antiviral activity against SARS-CoV-2 infected Vero E6 cells. The RDV-TNP-1 exhibited a significantly improved antiviral effect compared to RDV at the same concentration, which resulted in a more potent inhibition of SARS-CoV-2 replication in cell-based assays with respect to unloaded TNP (TNP-1E). Interestingly, TNP-1E also exhibited a basal antiviral activity, potentially due to a direct competitive mechanism with viral particles for the ACE2 binding site. We also measured the anti-exopeptidase activity of TNP-1E against ACE2 protein. Collectively, these insights warrant in-depth preclinical development for our nanoprototypes, for example as potential inhalable drug carriers, with the perspective of a clinical translation.

Novel beta-coronavirus SARS-CoV-2 is the pathogenic agent responsible for coronavirus disease 2019 and for the current global pandemic [1] [2] [3] [4] . This emergency highlights the urgent need to expand and focus current research tools on "neglected infectious diseases" to prevent future potential epidemics [5] [6] [7] [8] . Impressive efforts have been done at elucidating the viral structure, life cycle and to identify the potential targets in SARS-CoV-2 [9] [10] [11] [12] [13] [14] . Although some promising drug candidates are expected soon [15] , to date not novel approved antiviral pharmaceutical drugs exist.

Only one drug, the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir (RDV [15, 16] , brand name Veklury, developed by Gilead Sciences), with broad-spectrum activity against RNA viruses, has been issued by the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) as a treatment for hospitalized patients with severe COVID-19 symptoms [17] [18] [19] [20] [21] . Recent data showed that RDV can enhance clinical outcomes [22] , but its efficacy is limited by its poor physicochemical and pharmacokinetic properties that also prevent the feasibility of alternative routes such oral and intramuscular administration [23] . For this reason, the pulmonary delivery route by the inhalation may maximize direct delivery of RDV to the target site. This would avoid gastrointestinal proteolysis and hepatic first-pass metabolism, boosting local antiviral activity in the lungs, and limiting systemic off-target effects, thus improving its therapeutic profile [24, 25] as well as that of other antiviral agents currently involved in the development process. For example, since systemic adverse effects such as hepatotoxicity preclude escalation of the Remdesivir dose to more than 200 mg/day, (e.g. 100-200 mg of RDV is the current intravenous dose regimen in humans to achieve effective levels of drug against SARS-CoV-2), other therapeutic strategies which combine tools and different administration routes are needed [25] . This enzyme-related carboxypeptidase (i.e. ACE2) has high homology with the other ACE isoform, with approximately 40% sequence identity between ACE2 and ACE, and 60% similarity in the zinc binding on the catalytic domains [40] [41] [42] . It plays a key role in balancing the physiological levels of vasopressor octapeptide angiotensin II (Ang II), a component of the classical renin-angiotensin system (RAS), and the angiotensin (1-7) (Ang (1-7) [43] . In particular, by catalyzing the conversion of Ang II to Ang (1-7), ACE2 constitutes a regulator pathway of cardiovascular J o u r n a l P r e -p r o o f homeostasis [43] . Specifically, Ang (1-7) acts on Mas receptors producing cardiovascular protective functions and counter-regulating the detrimental effects of ACE/Ang II axis [44, 45] . Thus, the physiophatological role of ACE2 in the homeostatic regulation of cardiovascular system, as well as the vascular complications associated with COVID-19 disease, should be taken into consideration in studying its potential as a pharmacological target. For example, the implication of antihypertensive drugs targeting the cognate ACE, as well as Ang II-type 1 receptor (AT1R) blockers, to modulate the expression/function of ACE2, in order to putatively interfere with SARS-CoV-2 infection, have been disclosed recently [46] . The interaction of SP of SARS-CoV with ACE2 receptors can affect the RAS, inducing a cellular "protective" ACE2 shedding feedback response that initially attenuates viral entry [47] . Again, tumor necrosis factor-alphaconverting enzyme (TACE/ADAM17)-mediated ACE2 shedding, in combination with ACE2 enzymatic activity, have been shown to correlate positively with viral infection and related disease complications [48] [49] [50] . Collectively, these and other reports [51] [52] [53] indicate that, to date, it is not clear what is the downstream effect of the ACE2, and no clinical and consistent studies were reported for ACE2 inhibition, particularly in the interface with SARS-CoV-2 infection. However, the possibility to target ACE2 as an antiviral strategy appears to be attractive, and ACE2 targeted SARS-CoV-2 SP blockers hold greater promise. A significant example is represented by the lipoglycopeptide antibiotic dalbavancin, which directly binds to ACE2 with high affinity, thereby blocking the SARS-CoV-2 SP/ACE2 interaction, effectively inhibiting SARS-CoV-2 replication in vitro, and preventing viral infection and histopathological injuries in in vivo models [54] . Although other authors argue that it can be conceivable that targeting ACE2 provides an effective means for COVID-19 prevention and treatment [55] , this approach objectively requires careful consideration of the pros and cons of the availability of specific ACE2 modulators/targeting in the therapeutical armamentarium, as well as the clinical contexts in which they are likely to be effective.

Among various small molecules capable of targeting ACE2 [13] , to date, one of the most effective compounds is the His-Leu mimetic MLN-4760 (Chart 1B) [56] , which is reported to inhibit the J o u r n a l P r e -p r o o f catalytic activity of human ACE2 with an IC50 of 440 pM [56] (or low nanomolar concentration in other assays) [57] , and it has excellent selectivity versus related carboxypeptidase enzymes [43, 44] .

Structurally, the S,S diastereoisomer demonstrated the highest potency, compared to the other isomers [56, 57] . However, no antiviral SARS-CoV-2 data for MLN-4760 are available.

We thus hypothesized that ACE2 could be used as a key structure for targeted drug delivery by polymeric nanoparticles (NP), to improve the efficient transport of bioactive molecules/drugs and their specific and strong release in the ACE2 expressing cells, the primary target by SARS-CoV-2, which are expected to be infected by the virus. In fact, in our previous studies [58, 59] , inspired by Paul Ehrlich's concept of "magic bullet" [60] , we shifted the targeting paradigm in nanomedicine to enable enhanced selectivity of nanosystems for cells and tissues by a triple (tissue, cellular, molecular) targeting approach [31, 61, 62] .

On this idea, we recognised that a ligand capable of targeting ACE2 can be used to engineer nanosystems to obtain targeted NP (TNP). A suitable ligand chemotype should contain crucial features such as an appropriate pharmacophoric motif involved in chelation with the zinc metal ion on the active site, and a tail bearing a nucleophilic function (NF) to link with activated group (AG) of polymers used for nanoformulation (Chart 1C).

Herein, we report the design and development of novel biocompatible TNP covered by small organic molecules as targeting ligands in their polymeric shell surface, to selectively bind to ACE2 highly expressed in a model cell line (Figure 1) . We used pseudo-tri-block-copolymer PLGA-PEGligands as well as the parent di-block-copolymer PLGA-PEG-COOH to generate viral size comparable NP, which were characterized for their technological parameters, and evaluated for their biological profile by ACE2 binding affinity, competition assays (TNP vs SP model), ACE2 inhibition, antiviral activity for the most performing nanosystem loaded (and nonloaded) with RDV, and uptake and internalization into host cells. 

We designed the NP to target the ACE2 enzyme for site-directed antiviral drug delivery to cells potentially and primarily infected by SARS-CoV-2, with the aim of optimizing and validating their binding affinity against ACE2, and the antiviral impact of the most effective prototype. As a first step, we incorporated a fluorescent dye (Coumarin-6, C6) into polymeric NP conjugated to targeting ligands (Figure 1) , which allowed easy tracking. [63, 59, 64] , previously used as a prostatespecific membrane antigen (PSMA) targeting agent (PSMA is a glutamate carboxypeptidase which is highly expressed in prostate cancer cells and in nonprostatic tumor neovasculature) [65] , and b) the ACE1 inhibitor captopril (CPL, 3), which binds to the ACE active site [66] . Finally, since TACE/ADAM17 system take part in viral shedding [50] , we additionally tested a specific TACE inhibitor, i.e. the pseudo-peptide N-(R)-(2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl-L-tbutyl-glycine-L-alanine 2-aminoethyl amide (TAPI-2, 4) [13, 67] , as a ligand to bind to this putative additional target cell membrane (Figure 1) , which was also used as a negative control for ACE2

binding.

Based on the structural X-ray information of the ACE2 binding site with the inhibitor bound MLN-4760 [68] (for details see Experimental Section) and the abovementioned considerations, a comparative docking simulation study on ligands 1, 2, and 3, and on their respective polymeric constructs (PEG-ACL, PEG-DCL, and PEG-CPL, Figure S1A ) simulating the NP' terminus anchors (an amide bond for 1 and 2, and the maleimide conjugation for 3), was performed.

First, free 1, 2, and 3, were docked to the ACE2 active site, and crucial protein-ligand interactions were analyzed (Figures 2A, C, E) . In parallel, the corresponding interactions of alkyl-conjugatedligands (PEG-ACL, PEG-DCL, and PEG-CPL), were simulated ( Figures 2B, D, F) , and the binding modes of these model structures were compared. were in agreement with that of MLN-4760, as previoulsy reported [68] . Both ligands showed a consistent interaction with respect to the dicarboxylate moiety: the active site Zn 2+ metal ion is well Following the same strategy, the compound 4 and its polymeric model (PEG-TACE-2, Figure S1A )

were docked to TACE receptor [69] , and the effect of polymer conjugation was evaluated ( Figure   S1B ). Both the ligand 4 and its polymeric-based model mutually matched within the pocket, and a similar orientation pattern and disposition within the TACE catalytic site was observed. These evalutations support that the polymeric conjugated inhibitor can be consequently introduced onto the NP surface. PEGylation it is known to confer immune shielding properties to nanosystems, acting as a spacer between the targeting ligand and the NP surface. This starting carboxylate-functionalized di-blockcopolymer was activated to PLGA-PEG-NHS for the preparation of the tri-block-co-polymers (i.e., PLGA-PEG-1, PLGA-PEG-2, and PLGA-PEG-4) to obtain the TNP (Schemes 1 and 3) . Else, the thiol containing CPL (3) was reacted with maleimide terminal groups of PEG in the PLGA-PEGmaleimide (PLGA-PEG-mal) to obtain PLGA-PEG-3 (Scheme 2).

We prepared four sets of prefunctionalized biopolymer, the pseudo-tri-block-copolymers PLGA-PEG-1, PLGA-PEG-2, PLGA-PEG-3, and PLGA-PEG-4 (Schemes 1-3, Stage 1).

Synthesis of copolymers PLGA-PEG-1 and PLGA-PEG-2 (Stage 1) and (Schemes 1 and 3) . For conjugation, increased equivalent ratio of PLGA-PEG-NHS and 1 (from 1:4 to 1:10) improved the reaction efficiency. Preparation of activated block copolymer PLGA-PEG-NHS was carried out using a previous procedure (Scheme S1) [58, 64] . Conjugation of the targeting agents 3 to carboxylate PEG terminal group was performed using the electrophilic maleimide functionality of PEG activated carboxylic acids (Scheme S2). Reaction between the terminal -SH group of CPL (3) with PLGA-PEG capped maleimide resulted in the formation of PLGA-PEG-3 copolymer, which was synthesized by reacting the activated PLGA-PEG-mal with 3 in DMSO (Scheme 2, Stage 1). The intermediate PLGA-PEG-mal was prepared using a two-step reaction by conjugating bifunctional PEG, NH2-PEG-mal, to activated PLGA-NHS polymer, following a procedure previously described by our group (Scheme S1, and Supporting Information) [59] . The structure of PLGA-PEG-3 was also confirmed by 1 H-NMR spectroscopy, which revealed resonance shifts at 1.44-1.50, 3.51, 4.83-4.97, and 5.17-5.27 ppm, characteristics of PLGA-PEG backbone ( Figure S4 ). After conjugation, we observed a clear reduction of the maleimide methine free proton at 6.70 ppm of the PLGA-PEG-mal. Simultaneously, the appearence J o u r n a l P r e -p r o o f of a series of partially overlapped multiple peaks, especially in the aliphatic zone, attributable to the 3 signal pattern ( Figure S4 and Experimental Section for details) were detected.

Compound 1 was synthesized by revisiting the same methodology reported for the synthesis of

Synthetic route for the preparation of 1. On the other hand, the ligand DCL (2) was prepared following a procedure previously reported by us and by others [58, 64] , with slight modifications (Scheme S4, and Figures S11 and S12).

J o u r n a l P r e -p r o o f

To evaluate the binding affinity, the competition against the lentivirus-spike and cellular uptake of the NP, five batches of C6-encapsulated NP were successfully prepared using a modified nanoprecipitation method as previously described (Schemes 1, 2 and 3, stage 2) [58, 64, 71] . We used a blend of hydrophobic polymer PCL and amphiphilic block PLGA-PEG copolymers (PLGA-PEG-COOH, PLGA-PEG-1, PLGA-PEG-2, PLGA-PEG-3, and PLGA-PEG-4) to prepare nontargeted and targeted NP. During the nanoprecipitation in water, the polymers self-assemble to form NP, in which the hydrophobic PLGA blocks interact with the PCL into a core, minimizing their exposure to aqueous surroundings [72] . Simultaneously, the hydrophilic termini of the polymers (i.e. the carboxylate surfaces and PEG-1-4 flexible moieties) extend from the shell to stabilize the core by preventing degradation and aggregation. As mentioned above, PEG should impart "stealth" properties to the nanoconstructs, and the PEG methylene chain enables highaffinity binding of ligands to ACE2. Moreover, the spacer portion of the polymer would remain outside the tunnel as long as the pharmacophoric motif of 1, 2, 3, or 4 is anchored to the protein active site [73] .

All prepared NP batches showed well dispersed particles characterized by similar morphological properties, with a smooth surface and spherical shape (see below in Figure 5a as example). As summarized in Table 1 , the mean diameter of the NP ranged from 103 nm to 130 nm (analogous to a viral particle size), without significant differences within batches prepared with different copolymer conjugates. Only NP formulated with ACL (1) conjugated polymer exhibited significantly lower particle size (102.977.23 nm) compared with nontargeted batches. Each value is the mean  SD of triplicate determinations. *Significantly different from C6-NP-0 at p < 0.05.

In all cases, the NP dispersions were characterized by low PDI values (below 0.2) ( Table 1) ,

indicating a narrow and unimodal distribution, as a typical behavior of monodispersed systems (see below in Figure 5b as example) [74] . We detected a negativeζpotential for all bathches of C6-TNP-0/1/2/3, due to the presence of carboxylate groups on the PLGA-PEG termini. Also, C6-TNP-4 showed a negative ζ potential, which is coherent with their surface hydroxamic funtionalities.

With regard to the dye entrapment efficiencies, the obtained values resulted in about 75%, with no significant differences between the different NP batches, suggesting a good affinity between the polymeric blend and the dye loaded molecules. Moreover, yield of production ranging from 65-74%

were obtained for all preparations over multiple experiments.

The ability of the TNP to specifically bind to ACE2 protein, in comparison with the nontargeted A consistent affinity was also provided by the TNP-3, which was about 35% less effective than TNP-1. Conversely, the TNP-2 (carrying DCL) only showed a minimal residual interaction with ACE2. Finally, both the nontargeted NP (NP-0) and the TNP-4 did not exhibite any appreciable binding to the protein, as expected.

To evaluate whether the ACE2 targeting ability by NP is capable to provide a physical and topological blockage of SARS-CoV-2 binding with host cells, a competition experiment was carried out using rhodamine (Rho)-loaded liposome-derived SP (Lipo-S1) vs C6-loaded NP (in 1:1 ratio) in (measuring about 100 nm in size) were prepared according with the procedure we recently developed [75] . We observed that the C6 fluorescent TNP-1 strongly inhibited the SP model in binding to ACE2, with ~75% and ~25% for TNP-1 and Lipo-S1, respectively (Figure 4) . (Figure 3) , TNP-3 was also able to significantly compete (for ~50%) with Lipo-S1, whilst the TNP-2 (as well as TNP-4) did not show any evident binding interference. Finally, a certain quota of competition observed by NP-0 in these experimental conditions could warrant further mechanistic elucidation. These results demonstrated an excellent affinity of TNP-1 toward ACE2 receptor, thus supporting that this specific interaction would allow for selective binding toward host infected cells by the respective drug-loaded NP.

TNP-1 resulted the most performing targeting nanosystems in binding with ACE2, and it was thus selected to determine its ability to inhibit the SARS-CoV-2 replication in cell-based assays. TNP-1 loaded with RDV was developed to obtain a model of drug-encapsulated TNP, together with the corresponding unloaded NP (TNP-1E). Additionally, other two sets of Rho-TNP-1 and Rho-NP-0 for further uptake/internalization experiments ( Table 2 ) were prepared. Each value is the mean  SD of triplicate determinations. *E indicates "empty" NP.

The results indicated that TNP-1 batches displayed similar particle mean diameter (101 nm and 111 nm for RDV-TNP-1 and TNP-1E, respectively), independently of the drug loading, and exhibit a J o u r n a l P r e -p r o o f unimodal distribution with a PDI values of 0.105 (Table 2 and Figure 5) . Also, TNP-1 exhibited a good loading efficiency of RDV as confirmed from the obtained EE% and LC% values (51% and 1.03%, respectively). (Figures 6D and S13) . Ranging from the CTRL, with a complete absence of CPE, and the SARS-CoV-2 infected cells with a consistent production of CPE, we observed a dosedependent reduction of CPE production by the TNP-1 (as well as by RDV used as positive control), thus supporting the cytoprotective property of our prototypes.

To further substantiate the cytoprotective and antiviral activity results, we evaluated the ability of TNP-1 to inhibit SARS-CoV-2 in vitro by quantitative real-time polymerase chain reaction (qRT-PCR) assays, using 4-fold concentration scale ranging between 5 and 0.01 μM (Figures 7A-C) . The We also confirmed that unloaded NP were able to significantly reduce the SARS-CoV-2 replication at all concentrations tested, potentially due to the high affinity of the TNP-1 for the ACE2 receptor, which would prevent the viral entry. In our opinion, the targeting approach should not necessarily provide a more than two-fold difference in activity with respect to free drug, but should impart a site-specific drug delivery towards biological targets, which would allow to use a significant low dose of drug, to improve the PK of antiviral drugs and, most importantly, to prevent off-target distribution of a drug in the body. Moreover, RDV-TNP-1 resulted in about 2-fold highly active This general behaviour can be attributed to targeting ability of TNP-1 to ACE2, which promotes an enhanced binding between NP and the cells, thus resulting in increased adhesion in the membrane, and subsequent cell uptake through receptor-mediated endocytosis. Retrospective analysis on antiviral results allows to speculate that increased relative antiviral potency demonstrated by TNP-1, and the possibility to selectively deliver drugs to host cells, might be better highlighted in in vivo assays. In fact, while in the wells a drug diffuses through the cell membrane, the TNP would act by delivering the payload drug into the cells by a receptor (ACE2)-mediated endocytosis, thus preventing/reducing potential side effects.

To evaluate the putative ACE2 inhibition by TNP-1, we measured the effect of TNP-1E, compared with that of ligand 1, on the exopeptidase activity of recombinant human (rh)ACE2 employing a fluorometric assay (BPS Bioscience). We found that TNP-1E and 1 inhibited rhACE2 activity in the same concentration range (to compare both chemical entities the IC50s were determined and expressed as ng/mL), with TNP-1E being 3-fold more effective than the ligand 1 (IC50 = 1.407 and 4.215 ng/mL, for TNP-1E and 1, respectively, Figure 8 ). high avidity for the target receptor by the NP, which supports the targeting ability of TNP-1, but also induces inhibition of the ACE2 function. Although the interaction with the ACE2 receptor from any protein or particle could temporarily affect the RAS, the predicted short time for the antiviral treatment should not generate any significant interference or potential compensatory shift in the Ang II/Ang (1-7)/Mas receptor axis. Again, it should be taken into account that a single NP cannot be structurally compared with a small organic molecule ligand inhibitor such 1 or MLN-4760. To simplify this concept, we can assume that the inhibitory effect due to a single NP can be pursued by the same amount in weight of inhibitors, which should have a more consistent distribution and localization in the same district. Moreover, since SARS-CoV-2 prevalently infects (ACE2 enriched) epithelial cells in the respiratory system, our TNP-1 are suggested for inhalation route delivery, in order to limit the interference within ACE2-related pathways in cardiovascular system and kidney. Inhaled antiviral drugs can be localized to the target organ/tissues, especially if site-specifically targeted, which can allow for a lower dose compared to the systemic delivery. This would lead to reduced and less severe adverse effects concentration-dependent [29, 30, 81] .

However, although a low amount of TNP could statistically evade the respiratory tract, we should consider that polymeric NP are biocompatible/biodegradable materials, and that only a fewer amount of drug can be adsorbed in the systemic circulation with respect to the other administration routes. Inhibiting intracellular targets of the SARS-CoV-2 by targeted drug delivery, also J o u r n a l P r e -p r o o f preventing SARS-CoV-2 internalization by competing for the ACE2, may be effective in disrupting key protein/protein interactions involved in this pathogenic event [82] . Therefore, the benefit of our methodology can be higher than presumed side effects, which should be carefully evaluated in the next step of the study.

The correlation between antiviral activity of the nanosystems with cellular uptake was explored by uptake/internalization of Rho-loaded NP in Vero E6 cells, which were visualized by confocal fluorescence microscopy. Figure 9 shows images (scale bar 20 µm) of cellular uptake efficiency between targeted and nontargeted NP (Rho-TNP-1 and Rho-NP-0, respectively). 

After 3 h incubation, the Rho-TNP-1 showed higher cellular binding and uptake than the Rho-NP-0, as visible by a strong fluorescence in cell membrane and in the cytoplasm (Figure 9C) , which further confirmed their effective interaction with the targeted cells. This approach would support that TNP-1 will be internalized in the cell membrane, potentially via endocytosis. This putative mechanism can be triggered by targeting the ability of TNP-1 to ACE2, which results in cell uptake in stepwise manner. Importantly, antiviral results also confirm the effectiveness of the TNP-1, thus confirming an efficient endosomal escape of payload RDV, after disaggregation of the polymeric matrix in the cytosol. The selectivity of the endosomal mechanism by TNP-1, in terms of membrane diffusion/permeation cytosolic uptake by free drug, might have major impact in in vivo assays.

These results indicate that the TNP-1 prototypes were able to effectively address active compounds to ACE-2 expressing cells, potentially infected/infectable by SARS-CoV-2, building the basics for further optimization.

When the COVID-19 pandemic started, based on the structural and functional information available for SARS-CoV-2, we sought to develop engineered targeted nanosystems for ACE2 site-directed antiviral drug delivery which could represent a suitable and powerful approach to improve the antiviral profile of anti-SARS-CoV-2 therapeutics.

In this study, we developed drug-encapsulated NP targeting to ACE2 enzyme receptors, with TNP-1 demonstrated to be the most effective prototype. We highlighted that the TNP-1 efficiently binds to ACE2 receptors compared to the nontargeted ones, confirming similar behaviour when tested in 

1H-imidazole-1-carboxylate (6) [58] . Di-tert-butyl dicarbonate (Boc2O, 27.04 g, 123.92 mmol, 2 eq.) in MeOH (15 mL) was added dropwise to a solution of (S)-histidine methyl ester dihydrochloride 5 (15 g, 61.96 mmol, 1 equiv) in MeOH (150 mL, 0.4 M) and triethylamine (17.18 mL, 123.92 mmol, 2 equiv), and the reaction was stirred at r. t. for 24 h. Next, the solvent was evaporated and the residue was dissolved in CH2Cl2 and water, and then extracted three times with CH2Cl2. The organic phase was washed with brine, dried over Na2SO4, filtered and concentrated to provide a yellow oil, which was stored at -4-8 °C. An amorphous beige solid appeared, which was triturated with hexane to afford the di-Boc protected imidazole 6 as white solid (yield, 95%). 

To remove the Boc protecting group, the 

NP were prepared using a solvent displacement method previously reported with slight modifications [50, 51, 56, 63] . The ζ potential values of the NP were detected with a Zeta Plus analyzer (Brookhaven, USA) at 25

°C. Each sample of NP was diluted with distilled water (1.0 mg / 2.0 mL) and sonicated before measurement. All data were obtained with the average of three measurements.

To determine the fluorescent probe loading, a weighed amount of dye loaded NP was dissolved in The injection volume was 20 μL, the flow rate was 0.75 mL/min, the wavelength for UV detection was 254 nm, and the retention time was 11 min. The calibration curve was found to be linear in the range of 10-200 μg/mL (y = 40.262x + 83.739; R 2 = 0.9999).

The yields of production were expressed as the weight percentage of the final product after drying, regarding the initial total amount of solid materials used for the preparation. 

The data of NP characterization were processed by GraphPad Prism software (version 6, GraphPad software. Inc., San Diego, CA, USA) and subjected to one-way analysis of variance. Individual differences were evaluated using a nonparametric post hoc test (Tukey's test) and considered statistically significant at p < 0.05.

SARS-CoV-2, isolate USA-WA1/2020, was acquired from the Biodefense and Emerging Infections 

Construction of nano-liposomes (diameter = about 100 nm) containing S1 spike proteins (Lipo-S1), biotinylated to an external lipid bilayer, was performed as previously reported [75] . Briefly, Rhocontaining liposomes (Encapsula Nanoscience) prepared with Immunosome-Biotinyl Cap were coupled to SARS-CoV-2 S1 protein, His, Avitag (ACROBiosystems; No. S1N-C82E8), in a 1:2 ratio and excess S1 protein, dialyzed out from the liposome preparation. Control liposome preparations were prepared identically in the absence of SARS-CoV-2 S1 protein. 

C6-incorporated NP affinity bond with ACE2 was assessed through direct Elisa ACE2 (Abcam).

NP were incubated at 4°C overnight, then the plate was washed 5 times to eliminate the unbound NP, and binding between the ACE and NP was evaluated through fluorescence emission using a CLARIOstar® microplate reader (BMG Labtech). The C6 fluorescence signal was read at λex 488 nm λem 510 nm. Elisa ACE2 was also used to assess the competition between Lipo-S1 and NP, according with a published procedure [75] . Briefly, Rho-incorporated Lipo-S1 vs 6C-loaded NP were mixed in the ratio of 1:1 (0.98 μg/mL for each sample, considering the same amount of dye-J o u r n a l P r e -p r o o f loaded into NP) and incubated overnight at 4°C in the ELISA ACE2. Next, the Elisa plate was washed 5 times according to manufacture and binding between the hACE2 and Lipo-S1 or NP was evaluated through fluorescence emission using a CLARIOstar® microplate reader (BMG Labtech).

Fluorescent signal was read for Rho (λex 570 nm; λem ~610 nm) and 6C (λex 488 nmλem 510 nm).

AlamarBlue (AB) assay was used both to elucidate the inhibitory effect on CPE induction caused by SARS-CoV-2 infection and to assess the NP cytotoxicity. This assay was carried out according Positive (infected, non-treated with NP, and infected treated drug) and negative (non-infected, nontreated, non-treated exposed to propylene glycol medium with cells) control wells were also included. Each assay was carried out in triplicate. To score SARS-CoV-2 induced CPE, microscopy was performed in cells infected with virus, alone and after NP treatment. 

The ACE2 inhibitor screening assay kit (BPS Bioscience, San Diego, USA) was purchased to determine the exopeptidase activity of ACE2 and, consequently, its putative inhibition by TNP-1E

and ligand 1, using MLN-4760 as control inhibitor. The assays were performed according to the manufacture's protocol (catalog #79923). Briefly, enzyme (ACE2) stocks were prepared from the supplied kit; 20 μL of enzyme solution (0.5 ng/μL in ACE2 buffer) were added to each wells designated for the assay (considering positive "test inhibitors" and negative "blank" control). The 

The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

World Health Organization, Naming the Coronavirus Disease (COVID-19) and the Virus That Causes It

A new coronavirus associated with human respirator disease in China

A novel coronavirus from patients with pneumonia in China

COVID-19: living through another pandemic

Preparing for the next pandemic

Antiviral drug discovery: preparing for the next pandemic

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics

COVID-19: drug targets and potential treatments

Recent discovery and development of inhibitors targeting coronaviruses

Inhibitors of SARS-CoV-2 entry: current and future opportunities

Trends in COVID-19 therapeutic clinical trials

COVID antiviral pill: what scientists still want to know

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Remdesivir -an important first step

Remdesivir Emergency Use Authorization

Compassionate use of remdesivir for patients with severe Covid-19

Remdesivir for the treatment of Covid-19 -final report

Remdesivir for 5 or 10 days in patients with severe Covid-19

Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials

ADME and pharmacokinetic properties of remdesivir: its drug interaction potential

Development of remdesivir as a dry powder for inhalation by thin film freezing

Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer additional benefit

Nanoparticles for drug delivery to the lungs

Nanomedicine in pulmonary delivery

Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives

Polymeric nanoparticles in development for treatment of pulmonary infectious diseases

Inhaled nanoparticles-An updated review

Therapeutic potential of targeted nanoparticles and perspective on nanotherapies

Clinical translation of nanomedicine

Targeting strategies for tissue-specific drug delivery

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril insensitive carboxypeptidase

Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence

ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV

Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets

Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system

Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis

ACE2 in the era of SARS-CoV-2: controversies and novel perspectives

The Yin and Yang of ACE/ACE2 pathways: the rationale for the use of reninangiotensin system inhibitors in COVID-19 patients

Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensinconverting enzyme-2 (ACE2)

Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α-production and facilitates viral entry

interplay may be the main risk factor for COVID-19

The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity

Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models

Targeting ACE2 for COVID-19 therapy: opportunities and challenges

Substrate based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors

Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells

Targeted biocompatible nanoparticles for the delivery of

epigallocatechin 3-gallate to prostate cancer cells

Targeted nanoparticles for the delivery of novel bioactive molecules to pancreatic cancer cells

s magic bullet concept: 100 years of progress

Precision cancer nanotherapy: evolving role of multifunctional nanoparticles for cancer active targeting

Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation

A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer

Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy

The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy

Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin Iconverting enzyme

TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds

ACE2 X-ray structures reveal a large hingebending motion important for inhibitor binding and catalysis

Stabilization of the autoproteolysis of TNF-alpha converting enzyme (TACE) results in a novel crystal form suitable for structure-based drug design studies

Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. studies on direct and indirect reductive amination procedures (1)

Novel docetaxel-loaded nanoparticles based on poly(lactidecocaprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization and cytotoxicity studies

Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery

PEGylated nanoparticles for biological and pharmaceutical applications

What they are and what they are not?

Flow mediated susceptibility and molecular response of cerebral endothelia to SARS-CoV-2 infection

throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca/ts phenotype

Lack of antiviral activity of darunavir against SARS-CoV-2

Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors

Multivalency in supramolecular chemistry and nanofabrication

Multivalency and cooperativity in supramolecular chemistry

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation

Molecular dynamics and pharmacophore modeling studies of different subtype (ALK and EGFR (T790M)) inhibitors in NSCLC

Virtual screening and biological validation of novel influenza virus PA endonuclease inhibitors

Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function